Immix Biopharma prices 11,363,637-share offering at USD 11.00 per share for USD 125 million gross proceeds
Bitget2026/09/29 11:05- Immix Biopharma priced an underwritten offering of 11,363,637 common shares at USD 11.00 each.
- Gross proceeds expected at USD 125 million before underwriting discounts, commissions, and offering expenses.
- Closing expected on or about Sept. 30, 2026, subject to customary conditions.
- Net proceeds earmarked for NXC-201 development, working capital, and general corporate purposes.
- J.P. Morgan is sole book-running manager.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold Fields said to weigh sweetening Northern Star bid with cash
Under continuous pressure from inflation and interest rate hike concerns, US Treasury sell-off intensifies; 30-year yield once surpassed 5.6%, hitting a more than 24-year high
U.S. long-term Treasury yields continued to rise on Tuesday, extending the recent sharp upward trend.
The US releases the final batch of strategic oil reserves, up to 40 million barrels, urging Europe to follow suit.
This is the final batch of the 172 million barrels of reserves released by the United States in this round; after this release, the U.S. Strategic Petroleum Reserve will drop to its lowest level since 1982, approaching legal and operational red lines. Meanwhile, the U.S. Secretary of Energy criticized some European countries for releasing far less than expected, urging them to fulfill their commitments. Currently, gasoline and diesel prices in the U.S. remain high, and less than two months remain until the midterm elections. On Tuesday, WTI crude oil futures fell by 3.95%.
Raphael Zagury: Bitcoin will eventually surpass gold
Crypto prices
More
